Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Linperlisib in combination with CHOP

Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER